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HISTORY
The presence of hyperglycemia-producing properties in pancreatic extracts
and commercial insulin preparations was noted as early as 1923.'9"N, How-
ever, FisherM believed the hyperglycemic activity resided in a "toxic frac-
tion" which was also responsible for the local irritation and sterile abscesses
associated with insulin therapy; and Collip's extracts'9 produced an un-
usually prolonged hyperglycemia of one to four days' duration. It is there-
fore uncertain whether the hyperglycemic effect of these early extracts was
due to the specific hyperglycemic-glycogenolytic factor (HGF). In 1924,
Kimball and Murline gave the name "glucagon" to the factor, but the earli-
est intensive investigators of its properties were the German workers,
Burger and Kramer,'l who were dealing with the specific material and
who demonstrated that the hyperglycemic effect was due to direct glyco-
genolytic effect on the liver.
After the first successful crystallization of insulin by Abel et al.' in 1927,
Geiling and de Lawder,'' and Burger and Kramer," demonstrated that
crystalline insulin, even when injected intravenously, did not cause hyper-
glycemia. Glucagon was therefore considered merely an unimportant im-
purity, and during the next few years only Burger and his colleagues in
Germany continued its study. These workers were the first to attempt its
purification.8 In 1934 Scott'M succeeded in crystallizing insulin by a new,
highly efficient method which was widely adopted by most commercial
manufacturers. Insulin prepared by this method was found to have hyper-
glycemic and hepatic glycogenolytic properties.2" Lundsgaard et aL in 19397
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noted that a preparation of insulin provided by Scott stimulated the release
of glucose by the perfused liver, while a preparation of Abel's did not.
De Duve et al.24 demonstrated by means of constant intravenous glucose
infusions to insulinized rabbits that Lilly insulin (prepared by Scott's
method) was contaminated by the hyperglycemic factor, while a Danish
preparation ("Novo") made by the Abel technique was not. Olsen and
Klein76 confirmed the hyperglycemic properties of most insulin preparations
when given intravenously. "Novo" insulin was again an exception. This
and other work" '- 8' 88' '
so 9 100 presented strong evidence that insulin, per
se, has no direct glycogenolytic effect on the liver and resulted in a shift of
interest towards glucagon as an independent entity.
SITE OF ORIGIN AND DISTRIBUTION OF GLUCAGON
Sutherland and de Duve were able to extract the factor from the pancreas
of several species, including man."0'00 They suggested that the alpha cells of
the islets of Langerhans were the probable source because there were
increased amounts per unit weight in the fetal calf pancreas, in the tail of
the adult dog pancreas (where islets are concentrated), and in the duct-
ligated and alloxan-diabetic pancreas in which acinar and beta cells have
been destroyed. Pincus78 confirmed these findings in the dog. Audy and
Kerly"' noted a similar content of glucagon in pancreatic extracts from the
rabbit, rat, cat, guinea pig, and ferret and determined that in the Lophius
piscatorius, a teleost fish in which islet cell tissue is found outside the pan-
creas, extracts from islet cell tissue had a high content of glucagon, while
acinar tissue had minimal HGF activity. Sutherland and De Duve98'09 were
also able to extract a factor, apparently identical with HGF, from the upper
three-fourths of the gastric mucosa, and, in small quantities, from the
duodenum and ileum of the dog, but not from other tissues. They suggested
that the glucagon found in these sites may be formed by the argentophil
cells of the gastro-intestinal mucosa, which have a similar distribution and
which stain with silver as do alpha cells. Although the two groups of cells
are superficially similar, comparative morphological studies of Fodden'
have shown that they are not related physiologically.
The site of origin of HGF has also been studied by the use of specific
toxins. If glucagon is made in the alpha cells, destruction of these cells
should cause a decrease in the pancreatic HGF content and an increase in
the unopposed hypoglycemic action of the beta-cell hormone, insulin. In
1951, Van Campenhout and Cornelis"' reported selective destruction of
alpha cells after the administration of cobaltous chloride; and Vuylsteke,
Cornelis, and De Duve in 1952100 reported a decreased HGF content of the
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pancreas of animals pretreated with cobalt. Cavallero1' reported that pan-
creatic extracts from fish previously treated with cobalt had no hypergly-
cemic effects after alkali inactivation of insulin. However, other work with
cobalt has failed to confirm some of the above findings and does not support
the concept of the alpha cell origin of the HGF. Goldner, Volk, and Lazarus
have demonstrated that hyperglycemia following immediately after cobalt
administration is not due to a predestructive "excitation initiale" of the
alpha cells, as proposed by Van Campenhout and Cornelis,'0 but occurred
regardless of the intervals between successive doses151 and increased with
increasing doses of cobalt51; indeed, the initial hyperglycemia occurred in
the pancreatectomized animal.' The hepatic glycogen content of cobalt
treated animals was decreased. They therefore ascribe the hyperglycemic
response to a direct hepatic effect of cobaltous ions.1' These authors also
reported that following destruction of the alpha cells by cobalt, there was no
hypoglycemia,"M no amelioration of alloxan diabetes,°' and a persistence of
hyperglycemic activity in pancreatic extracts.' Raja Rama Rao and De,'
working with rabbits, noted no decrease in HGF content of the pancreas
after cobalt administration. These authors also claim to have detected HGF
in the abdominal lymphatics and spleen as well as in the pancreas and
gastric mucosa, and, on this basis, suggested abdominal lymphatic tissue as
the source of HGF. However, they do not mention their method of
extraction. I
Deca methylene diguanidine hydrochloride, or Synthalin A, was shown
by Davis,' in 1952, to produce a selective but inconstant hydropic change
of the alpha cells in rabbits. These changes are not nearly as extensive as
those caused by cobalt, but are followed by a hyperglycemia of several
hours' duration, and then marked hypoglycemia. Fodden,"7'2 comparing the
effects of cobalt and Synthalin A, suggested that cobalt causes a retention
of HGF in the alpha cells, while Synthalin A, after causing an initial secre-
tory discharge of HGF, inhibits completely the HGF function of the cells.
He believes that this explanation reconciles the incompatabilities between
alpha cell destruction and glycemic effects of the two compounds, and that
his work supports the alpha cell origin of pancreatic HGF.
In summary, there is abundant evidence of the presence of a factor pro-
ducing hyperglycemia and hepatic glycogenolysis in the pancreas of all
species that have been assayed for the substance. The bulk of evidence sup-
ports the alpha cells as the pancreatic cellular site of origin. The main ob-
jection to this concept is the inconsistent effect obtained with the specific
cytotoxins. However, for several reasons, work with the cytotoxins cannot
be evaluated completely at this time. Neither of the toxic compounds has
been shown to destroy all of the alpha cells, and although cobalt in some
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dosages appears to produce considerable alpha cell damage, its effects on
other gastro-intestinal sources of HGF are unknown. Indeed, Fodden'
noted no effect on the gastro-intestinal argentaffin cells after either cobalt
or Synthalin A. Furthermore, these substances may not affect carbohydrate
metabolism entirely by damaging alpha cells, since both probably have
primary hepatic glycogenolytic activity.
PROPERTIES AND POTENCY
A detailed account of the methods of extraction and the physical and
chemical properties of the pancreatic HGF is not within the scope of this
paper. Suffice it to say that HGF is apparently a polypeptide physically
somewhat similar to insulin but differing from the latter in its amino acid
composition, and its resistance to alkali and cysteine incubation.' It has
been demonstrated that the hyperglycemia obtained with cysteine-inactivated
pancreatic and gastric extracts is due to HGF and not to the hyperglycemic
effect of cysteine itself." HGF has been extracted in a purified crystalline
form by Staub et al.' It can be assayed in vivo by measuring the hyper-
glycemic effect, but its glycogenolytic effect on rabbit liver slices"'98.9 is the
most accurate method. The material is extremely potent in its purified
form, 0.1 ug./Kg of body weight causing a significant hyperglycemia in the
cat"; as FoA67 points out, on a weight basis, the potency of HGF is at least
ten times greater than that of insulin.
Carbohydrate metabolism. The best-established effect of HGF is the
production of a rapid, transient hyperglycemia, accompanied by marked
glycogenolysis in the liver." The fact that this hyperglycemia is most
marked after intraportal injection,10'18 that it is absent in the hepatectomized
animal,"2'" is increased when liver glycogen content is high,59'91 and dimin-
ished in situations where liver glycogen is decreased-as in diabetic animals
in ketosis,""" in patients with cirrhosis,'m and in fasting animals'0-°all
attest to the primary hepatic site of action. Sutherland and Cori"9 have
conclusively demonstrated that the glycogenolytic effect of HGF, like that
of epinephrine, is on the liver phosphorylase system, both agents probably
acting upon a liver enzyme that maintains a balance between active and
inactive phosphorylase. However, despite their similarities with respect to
hyperglycemic and hepatic glycogenolytic effects, HGF and epinephrine
have numerous points of difference. Epinephrine causes an increase in
blood lactate levels, a result of its glycogenolytic effect in muscle, and this
lactate secondarily replenishes hepatic glycogen stores.2' HGF does not
cause increased blood lactate levels after administration to normal ani-
mals'"' or normal or diabetic human beings.' Furthermore, HGF does
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not have the pressor influence on blood pressure and pulse that epinephrine
manifests."'0
The fact that epinephrine has effects on muscle tissue slices' and in the
hepatectomized animal' is confirmatory of its peripheral, extra-hepatic
activity. There are few data to support such activity on the part of HGF.
The most impressive evidence of an extra-hepatic action of glucagon is the
work of Drury, Wick, and Sherrill" who maintained eviscerated, nephrec-
tomized rabbits at constant blood sugar levels by accurately measured
intravenous glucose injections. Some were given insulin simultaneously.
On the basis of the amount of glucose required to maintain constant blood
levels, these authors reported that glucose transfer was decreased during
HGF administration and suggested that HGF may play a role as an in-
sulin antagonist. HGF, like insulin, had no effect on the rate of glucose
oxidation, however. Rodriguez-Candela7 has reported that HGF inhibits
the deposition of glucose in the isolated rat diaphragm in the presence of
insulin. HGF alone, however, had no effect. Young"' was unable to confirm
these results; nor could Mirsky" demonstrate any effect of HGF on gly-
cogen synthesis in the rat diaphragm. Pincus and Rutman," working with
normal dogs, reported that HGF results in an increase in muscle glycogen
in the presence of insulin. Engel and Scott"' have reported that HGF had
no effect on glycogen synthesis in rat adipose tissue.
Lipid metabolism. Haugaard and Stadie," and Haugaard and Haugaard'7
working with rat liver slices, found a decrease in fatty acid synthesis in the
presence of HGF, as measured by the incorporation of radioactive labeled
acetate, glucose, or fructose into fatty acids. These authors point out that
the decreased specific activity of the fatty acids produced under their ex-
perimental conditions might be explained on the basis of a dilution of the
pool of fatty acid precursors with glucose released by the glycogenolysis
induced by HGF but they believe that the amount of glycogenolysis was
inadequate to explain the effects they observed. Haugaard and Haugaard
also noted an increased ketone body synthesis in liver slices treated with
HGF. Foa and Weinstein,43 44 working with diabetic dogs, found an in-
creased ketonemia after administration of a Lilly purified HGF, but using
other crude pancreatic extracts, they noted a hyperglycemic effect with a
marked decrease in blood ketones. These authors suggest that there is a
pancreatic factor, distinct from insulin and HGF, which is capable of
decreasing the blood ketone levels. Stewart and Roitman9 obtained no
effect on ketone production by rat liver slices after treatment with Lilly
purified HGF or various aqueous pancreatic extracts. Zimmermann and
Donovan"' gave cysteine-inactivated insulin preparations as a source of
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HGF to depancreatized dogs untreated with insulin and noted a brief
increase followed by a prolonged diminution in ketonemia. These changes
accompanied a similar brief hyperglycemia and prolonged hypoglycemia in
the dogs. Kalant,' using fasted rats and intraperitoneal Lilly purified HGF,
also noted a significant decrease in ketonemia acutely, and an inhibition of
ketosis during fasting. It should be noted that this author reported no sig-
nificant accompanying hyperglycemia nor depletion of liver glycogen, and
although the absence of these phenomena can probably be explained by the
fact that the animals were in the fasted state and that blood samples for
analysis were apparently taken two hours after the last dose of HGF, the
efficacy of HGF administered by the intraperitoneal route is open to ques-
tion.8" Rutman, Pincus, Brown, and Scott,' found no changes in blood
acetone levels of intact and pancreatectomized dogs after HGF administra-
tion. The blood lipids did not change in glucagon-treated dogs when com-
pared to saline- or insulin-treated controls.' Pincus and Rutmane reported
that HGF did ameliorate the acidosis of diabetic dogs. Bondy and Cardillo
were unable to produce ketosis by intravenous glucagon in fasted normal
human beings.6
The observed effects of HGF on fat metabolism have been contradictory.
The pathways of lipid and carbohydrate metabolism are closely interrelated
and converge to a common enzyme system at the level of acetyl-Co-A. The
effect of glucagon on ketosis, therefore, may depend on its ability to alter
the liver glycogen and the availability of glucose to the liver and peripheral
tissues. The variability of the reported effects probably results from the
variety of conditions under which the tests have been performed, and the
consequent variations in the basic substrate on which the hormone could
act. There is no clear-cut evidence that glucagon has any effect on fat
metabolism except as a consequence of the primary alterations it produces
in carbohydrate metabolism.
Protein mzetabolism. The role of the HGF in protein metabolism has not
as yet been investigated. Tyberghein,1" measuring urinary nitrogen excre-
tion in rabbits, reported that HGF accelerates protein catabolism.
DIABETOGENIC ACTIVITY
The effect of pancreatectomy on experimental diabetes caused by insulin
deficiency. If the pancreatic hyperglycemic factor is diabetogenic, it should
be possible to alleviate established experimental diabetes caused by beta-cell
destruction by removal of the remainder of the pancreas. Experiments of
this type have been carried out by a number of authors. Young, in 1939,'
reported that dogs made permanently diabetic by injections of anterior
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pituitary extracts required more insulin than pancreatectomized dogs on a
similar diet. Dragstedt, Allen, and Smith' noted that dogs who were 90%o
to 95 o depancreatized required more insulin to maintain minimal glyco-
suria than a similar series of totally depancreatized animals. Cavallero and
Malandra" reported that removal of 90%o of the pancreas reduces the glyco-
suria and fasting blood sugar, and increased the insulin sensitivity of
alloxan-diabetic rats. Thorogood and Zimmermann, in 1945,'°' reported
that pancreatectomy in alloxan-diabetic dogs reduced the glycosuria and
insulin requirements. These authors also noted that ketosis and coma devel-
oped more rapidly in the pancreatectomized dogs after insulin withdrawal
and suggested that there might be an alpha cell hormone which acts in
opposition to insulin in respect to blood sugar and glycosuria and which
prevents ketosis and coma in the insulin-deficient animal.
Opposed to this explanation is the opinion of Mirsky." This investigator
confirmed the findings of Thorogood and Zimmermann"' and of Rodriguez-
Candela8 that the quantity of glucose excreted in the urine by the alloxan-
diabetic dog on a constant regimen of food and insulin is decreased after
pancreatectomy, and that, therefore, the pancreatectomized animal will have
lower insulin requirements if glycosuria is the criterion for control. How-
ever, this decreased glycosuria was not accompanied by a weight gain; after
pancreatectomy of alloxan-diabetic animals, there was an increase in hyper-
glycemia, ketonemia, and glycosuria during periods of fasting and of insulin
deprivation; despite administration of sufficient pancreatin to prevent fatty
stools and fatty infiltration of the liver in the pancreatectomized dogs, such
dogs absorbed considerably less protein than alloxan-diabetic dogs: the
alloxan-diabetic dogs have appreciable stores of liver glycogen, since they
developed a marked ketonemia only after the administration of phlorizin
with consequent depletion of liver glycogen. On the basis of these findings,
Mirsky concluded that the "amelioration" of alloxan diabetes by pancreatec-
tomy is on the basis of decreased protein absorption with a resulting dimi-
nution of carbohydrate precursors, and that the resistance to ketosis and
coma in the alloxan-diabetic animal before pancreatectomy is on the basis of
the ability of these animals to store large quantities of glycogen. He would,
therefore, ascribe the differences between alloxan-diabetic and pancreatec-
tomized animals to the exocrine rather than to the alpha cell function of the
pancreas. There are certain experiments which seem to contradict this
theory. Thus, Thorogood and Zimmermann'0' and Rodriguez-Candela'
noted no decrease in the insulin requirement of the alloxan-diabetic dog
after ligation of the pancreatic duct, while the removal of the remaining
sclerosed pancreas did result in a decreased insulin requirement. However,
Thorogood and Zimmermann reported on only two dogs subjected to duct
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ligation and Rodriguez-Candela offers no details as to the observations he
reported. These experiments have also been criticized because the dogs
were not observed long enough after ligation of the pancreatic duct to per-
mit a defect of protein absorption to develop.
Cavallero and Malandra''l' reported that pancreatic grafts from
alloxan-diabetic, but not from normal, rats reduced the glucose tolerance
and increased the insulin resistance of rats made diabetic by partial pan-
createctomy.
Total pancreatectomy in man. In recent years a limited number of totally
depancreatized human beings have been available for observation. Although
many of the patients die too soon postoperatively to permit adequate
metabolic study, a few have been investigated in some detail months after
surgery and in a more or less stable condition. Dixon et al.,' Ricketts et al.,'
and Fallis and Szilagyi'8 have reported the results of total pancreatectomy
in previously diabetic patients. Summaries of studies on depancreatized
humans have been published by Whipple in 19461 and Gourevitch,
Thomas, and Whitfield in 1952." In general, these patients require less
insulin than many ordinary diabetics, since their maintenance dosage
usually falls in the range of twenty to forty units daily. The previously
diabetic patients required about the same amount of insulin as preopera-
tively. However, these patients all suffer from defective nitrogen and fat
absorption, the number adequately studied has been small, the criteria for
regulation are not uniform, and individual complicating variations are
numerous, so that little clarification of the r6le of HGF as a diabetogenic
agent has come, as yet, from studies of pancreatectomized humans.
Experimental production of diabetes by HGF. Cavallero and Malandra1e
reported that HGF increased the blood sugar levels and glycosuria in rats
force-fed a diet high in carbohydrate, and that it enhanced significantly the
hyperglycemic and glycosuria effects of pituitary growth hormone, adreno-
corticotropic hormone, and cortisone. Glucagon, while not diabetogenic it-
self, potentiates the diabetogenic effects of cortisone in respect to glycosuria,
fasting blood sugar levels, and glucose and insulin tolerance tests in intact,
ad. lib. fed rats."7 However, cortisone diabetes is characterized by elevated
hepatic glycogen stores and the demonstration that HGF, with its marked
hepatic glycogenolytic action increases the glycosuria and basal blood sugar
levels of these animals is not significant evidence of a true diabetogenic
effect. Ingle, Beary, and Purmalis' noted that HGF produced a definite but
temporary enhancement of glycosuria in partially depancreatized rats. This
effect was produced only when HGF was administered by intravenous
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infusion, and the glycosuria returned to pretreatment levels while HGF
was still being administered.
The effects of HGF have been studied in humans in an effort to deter-
mine whether a state of hyperglycemia associated with decreased peripheral
utilization of glucose could be produced. Van Itallie et al.'0 administered
HGF by infusion to normal subjects in the postabsorptive state and re-
ported that the HGF-induced hyperglycemia was accompanied by an in-
creased difference in the levels of arterial and venous glucose. This finding
indicates that there is no inhibition of peripheral glucose transfer under the
influence of HGF as there is after epinephrine administration. Indeed, the
work of these authors suggested that HGF might enhance glucose transfer
on the basis of comparable determinations in subjects to whom glucose had
been administered. Bondy and Cardillo' confirmed these findings in their
series, and in addition noted that glucagon and glucose caused comparable
decreases in blood inorganic phosphorus and alpha amino nitrogen levels.
Kirtley et al. also produced a fall in serum inorganic phosphorus levels
in normal subjects during and after HGF administration. A reduction of
the levels of inorganic phosphorus appears to be a reliable manifestation of
peripheral hexose transfer in normal subjects.6
There has been no report of permanent experimental diabetes resulting
from HGF administration.
Increased alpha to beta cell ratio as the etiology of diabetes mellitus.
Ferner"'S suggests that the anatomical basis of human diabetes mellitus is
an increased ratio of alpha to beta cells, with a resulting predominance of
the "glucagon system" over the insulin system. He supports his theory with
morphological studies of the islets of normal and diabetic humans""
" 101 as
well as the aforementioned investigations relative to the effect of total pan-
createctomy on alloxan-diabetes, and by the well-known phenomenon of
"amelioration' 'of pancreoprivic diabetes by hypophysectomy (with con-
sequent removal of the alleged "alphacytotrophic principle" of the anterior
pituitary). However, pancreatectomy removes the chief source of glucagon,
and it is therefore most unlikely that any important part of the effect of
hypophysectomy on the diabetes of pancreatectomized animals is a result of
removal of the stimulus to the extra-pancreatic sources of HGF. The ques-
tion of the "amelioration" of alloxan-diabetes by pancreatectomy has al-
ready been discussed. As Fabrykant" points out, different investigators are
not in complete agreement as to the normal range of the alpha: beta ratio.'M
Furthermore, Ferner himself has demonstrated that there is an increased
alpha: beta ratio in newborns, who ordinarily have low levels of blood
glucose.'
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Hyperglycemic substances in diabetic urine. One investigator'7 has re-
ported the presence of a hyperglycemic-glycogenolytic factor in the urine of
diabetic patients and alloxan-diabetic rats and rabbits, when the blood sugar
levels were elevated above 200 mgm%. The action of this substance was
destroyed by tryptic digestion and the author suggests that it is probably of
pancreatic origin. Another report'1' of a hyperglycemic factor in diabetic
urine suggests that the responsible substance is not a protein. Work in this
line cannot be evaluated at this time.
HGF AS A MEDIATOR OF THE EFFECTS OF GROWTH HORMONE
It has been suggested that there is a relationship between an anterior
pituitary "alphacytotrophic factor" closely related to growth hormone
(STH) and the HGF, and that the HGF may mediate the diabetogenic
effects of STH."' The effects of purified growth hormone are reviewed by
Young."' For the purposes of this discussion it can be pointed out that in
animals these preparations have well-established growth accelerating prop-
erties which can be measured by epiphyseal cartilage growth or by the
production of positive nitrogen balance, and that they have definite dia-
betogenic properties in some species. The evidence linking the growth
hormone and HGF is as follows:
Histologic studies after hypophysectomy or adninistration of anterior
pituitary extracts. Sonenberg92 reported that isotopically-labeled growth
hormone is concentrated in the pancreas. Ferner' found that hypophysec-
tomy was associated with atrophy and a decrease in number of alpha cells,
with no alterations in beta cells in all of the guinea pigs, and in one-half of
the rats in his series, but in five or six months the cell pattern returned to
normal. He also reported increased numbers of alpha cells as compared to
the number of beta cells in human embryos and newborns and cited this
finding as evidence associating the growth hormone, alphacytotrophic fac-
tor, and alpha cell system. Ham and Haist' treated dogs with daily injec-
tions of anterior pituitary extract and reported evidence of alpha cell de-
granulation in a small percentage of their animals. Cavallero" reported that
rats pretreated with growth hormone preparations showed a marked in-
crease in the ratio of mitotic activity of alpha cells to beta cells. Similar
observations were made in dogs made diabetic by anterior pituitary extract
injection. They also treated normal dogs with pancreatic extracts from
these "Young diabetic" dogs and from normal animals and reported a more
marked and prolonged hyperglycemia in the former animals.
Secretion of HGF in response to growth hormone. Bornstein, Reid, and
Young' noted a hyperglycemic and glycogenolytic effect of portal or
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pancreatico-duodenal venous blood but not of peripheral blood in intact and
adrenalectomized hypophysectomized alloxan-diabetic animals treated with
growth hormone. Growth hormone by direct injection and blood from
saline-treated control animals failed to elicit the HGF effects in the animals
used for assay. Foa et al.' reported that blood from the pancreatico-
duodenal vein, but not from the mesenteric vein of donor dogs treated with
growth hormone, caused a transient hyperglycemia in recipient dogs that
was similar to the typical response to HGF. Blood from control animals
injected with control solutions of the identical pH had no hyperglycemic
effect.
It is important that growth hormone is capable of producing permanent
diabetes in experimental animals,'1 but that HGF, even in high sustained
dosages, is not. This does not support the concept that the diabetogenic
effects of growth hormone are mediated entirely by HGF.
Somatotrophic effects of HGF. Elrick' treated hypophysectomized rats
with HGF and reported that in most instances there was a significant in-
crease in epiphyseal cartilage growth as compared to controls. He suggested
that both the diabetogenic and growth-stimulating actions of growth hor-
mone are mediated, in part or wholly, through the release of HGF. How-
ever, Geschwind and Staub,' using highly purified HGF preparations, were
unable to confirm these results.
CURRENT STATUS
Is glucagon a hormone? It is a substance which exerts its effects on a
distant organ and is potent in minute doses. It probably is formed chiefly in
the alpha cells of the pancreas. Cavallero points out'2 that these cells have
the characteristics of an independent endocrine organ, since they show mor-
phological evidence of secretory activity, and their reactions to cytotoxins
and physiological and pathological conditions are independent of the beta
cells and the acini. The cross-circulation experiments of Foa and his col-
laborators"'2 have established the fact that the pancreas secretes a hyper-
glycemic substance into the blood stream in response to insulin-induced
hypoglycemia. Work with perfusion of the isolated rat pancreas suggests
the same conclusion.2"' It has been impossible, however, to produce a pure
and total deficiency of HGF. The rapid action and potency of glucagon and
the evidence afforded by cross circulation experiments indicate that the
HGF is probably one of the factors responsible for the regulation of blood
glucose levels in the intact animal, possibly in response to anterior pituitary
stimulation under some circumstances. Engel suggests' that HGF, like
epinephrine, is involved in the early response to hypoglycemia. However,
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the failure to obtain permanent hypoglycemia after destruction of most, if
not all, of the alpha cells by cobalt, the demonstration that the response to
hypoglycemia is not altered by pancreatectomy,6' the fact that liver glyco-
gen is not diminished in alloxan-diabetic animals7'" and the transient nature
of HGF effects make it unlikely that the HGF plays a dominant role in
metabolic homeostasis.
Glucagon is often referred to as an "anti-insulin" factor. This statement
is true only in the most limited sense. It is true that, whereas insulin
reduces the concentration of glucose in the blood, glucagon raises it; but
these effects are produced in totally different sites and by unrelated mechan-
isms. Thus insulin appears to act chiefly on the peripheral tissues by in-
creasing the entry of glucose into the cellular metabolism,"' whereas
glucagon acts chiefly by promoting the breakdown of liver glycogen and its
release as glucose into the blood. It is therefore clear that glucagon and
insulin act synerigistically, the former by making liver glycogen stores
available for the peripheral action of the latter. In insulin-deficient ani-
mals? "' and human beings before hepatic glycogen is depleted' the
hyperglycemic effects of HGF are exaggerated, but this is doubtless because
under these circumstances the second link in the chain-insulin-is absent.
There is, therefore, no convincing evidence of any peripheral effect of
HGF; indeed, at this time, the only effects that can be considered estab-
lished are its hyperglycemic and hepatic glycogenolytic properties, which
were demonstrated by Burger and Kramer more than thirty years ago.
REFERENCES
1. Abel, J. J., Geiling, E. M. K., Rouiller, C. A., Bell, F. K., Wintersteiner, O.:
Crystalline insulin. J. Pharmacol., 1927, 31, 65.
2. Anderson, E. and Long, J. A.: The hormonal influences on the secretion of
insulin. Recent Progr. Hormone Res., 1948, 2, 209.
3. Anderson, E. and Long, J. A.: The effect of hyperglycemia on insulin secretion
as determined with the isolated rat pancreas in a perfusion apparatus. Endo-
crinology, 1947, 40, 92.
4. Audy, G. and Kerly, M.: The content of glycogenolytic factor in some insulin
samples. Biochem. J., 1952, 52, 70.
5. Audy, G. and Kerly, M.: The content of glycogenolytic factor in pancreas from
different species. Biochem. J., 1952, 52, 77.
6. Bondy, P. K. and Cardillo, L. R.: in press.
7. Bornstein, J., Reid, E., and Young, F. G.: The hyperglycaemic action of blood
from animals treated with growth hormone. Nature (Lond.), 1951, 168, 903.
8. Burger, M. and Brandt, W.: tTber das Glukagon (die hyperglykamisierende
Substanz des Pankreas). Z. ges. exp. Med., 1935, 96, 375.
9. Burger, M. and Kramer, H.: tYber den hepatischen Angriffspunkt des Insulins.
Die primare Paradoxe Insulinhyperglykiimie. Z. ges. exp. Med., 1929, 65, 487.
10. Burger, M. and Kramer, H.: Primare Hyperglykamie und Glykogenveranderung
der Leber als Folge intraportaler Insulininjektion nach Untersuchungen am
Hund. Z. ges. exp. Med., 1929, 67, 441.
132Glucagon (hyperglycemic-glycogenolytic factor) I CARDILLO, BONDY
11. Burger, M. and Kramer, H.: Uber die Wirkungsverschiedenheit technischer
Insuline und kristallisierter Praparate bezuglich der primaren Insulin-
hyperglykamie. Arch. exp. Path. Pharmak., 1930,156, 1.
12. Cavallero, C.: etudes sur le facteur hyperglycemiant du pancreas. Rev. canad.
Biol., 1953, 12, 509.
13. Cavallero, C. and Malandra, B.: Sul'effeto diabetogeno degli innesti di pancreas
nel ratto. Arch. Sci. biol. (Bologna), 1950, 34, 138.
14. Cavallero, C. and Malandra, B.: Effetto della pancreasectomia subtotale sul
diabete allossanico del ratto. Boll. Soc. ital. Biol. sper., 1949, 25, 85.
15. Cavallero, C. and Malandra, B.: Sul'effetto diabetogeno dei trapianti di pancreas
allossanato nel ratto. Boll. Soc. ital. Biol. sper., 1949, 25, 87.
16. Cavallero, C. and Malandra, B.: Hyperglycemic and glycosuric effect of gluca-
gon in the intact force-fed rat. Acta endocr., 1953, 13, 79.
17. Cavallero, C., Malandra, B., and Galansino, G.: Diabetogenic action of pancre-
atic glucagon. Nature (Lond.), 1954, 173, 585.
18. Collens, W. S. and Murlin, J. R.: Hyperglycemia following the portal injection
of insulin. Proc. Soc. exp. Biol., (N. Y.), 1929, 26, 485.
19. Collip, J. B.: Delayed manifestation of the physiological effects of insulin follow-
ing the administration of certain pancreatic extracts. Amer. J. Physiol., 1923,
63, 391.
20. Cori, G. T. and Cori, C. F.: The formation of hexosephosphate esters in frog
muscle. J. biol. Chem., 1936, 116, 119.
21. Cori, G. T., Cori, C. F., and Buchwald, K. W.: The mechanism of epinephrine
action. V. Changes in liver glycogen and blood lactic acid after injection of
epinephrine and insulin. J. biol. Chem., 1930, 86, 375.
22. Davis, J. C.: Hydropic degeneration of the a cells of the pancreatic islets pro-
duced by synthalin A. J. Path. Bact., 1952, 64, 575.
23. De Duve, C., De Nayer, P. P., Van Oostveldt, M., and Bouckaert, J. P.:
Nouvelles recherches concernant l'action de l'insuline. II. Action de l'insuline
chez l'animal normal, hepatectomize et eviscere. Arch. int. Pharmacodyn.,
1945, 70, 78.
24. De Duve, C., Hers, H. G., and Bouckaert, J. P.: Nouvelles recherches con-
cernant l'action de l'insuline. VI. Action de l'insuline sur le glycogene du foie.
Arch. int. Pharmacodyn., 1946, 72, 45.
25. De Duve, C. Hers, H. G., and Bouckaert, J. P.: La pretendue action glyco-
genolytique de l'insuline. C. R. Soc. Biol. (Paris), 1947, 141, 1147.
26. Dixon, C. F., Comfort, M. W., Lichtman, A. L., and Benson, R. E.: Total pan-
createctomy for carcinoma of the pancreas in a diabetic person. Arch. Surg.,
1946, 52, 619.
27. Dragstedt, L. R., Allen, J. G., and Smith, E. M.: Extensive insulin tolerance in
diabetic dogs. Proc. Soc. exp. Biol. (N. Y.), 1943, 54, 292.
28. Drury, D. R., Wick, A. N., and Sherrill, J. W.: The effect of the hyperglycemic
factor on the metabolism of glucose by the extrahepatic tissues. Diabetes, 1954,
3, 129.
29. Elrick, H.: Pancreatic hyperglycemic factor and growth. Proc. Soc. exp. Biol.
(N. Y.), 1953, 82, 76.
30. Engel, F. L.: The endocrine control of metabolism. Bull. N. Y. Acad. Med.,
1953, 29, 175.
31. Engel, F. L. and Scott, J. L., Jr.: The role of hormones in adipose glycogen
synthesis in the rat. Insulin and the hyperglycemic factor of the pancreas.
Endocrinology, 1950, 46, 574.
32. Fabrykant, M.: The alpha cells of pancreatic islets and the pathogenesis of
diabetes mellitus. Amer. J. dig. Dis., 1953, 20, 275.
133YALE JOURNAL OF BIOLOGY AND MEDICINE Volume 28, November 1955
33. Fallis, L. S. and Szilagyi, D. E.: Observations on some metabolic changes after
total pancreatoduodenectomy. Ann. Surg., 1948, 128, 639.
34. Ferner, H.: Das Inselsystem des Pankreas. Stuttgart, George Thieme, 1952.
35. Ferner, H.: The A- and B- cells of the pancreatic islets as sources of the
antagonistic hormones glucagon and insulin. The shift of the AB relation in
diabetes mellitus. Amer. J. dig. Dis., 1953, 20, 301.
36. Fisher, N. F.: Preparation of insulin. Amer. J. Physiol., 1923, 67, 57.
37. Foa, P. P.: Glucagon, the hyperglycemic-glycogenolytic hormone of the pancreas.
Advanc. intern. Med., 1954, 6, 29.
38. Fo'a, P. P.: Glucagon, the anti-insulin hormone of the pancreas. Chicago med.
School Quart., 1953, 14, 145.
39. Foa, P. P., Berger, S., Santamaria, L., Smith, J. A., and Weinstein, H. R.:
Extraction of the hyperglycemic factor (HGF) of the pancreas with liquid
ammonia. Science, 1953, 117, 82.
40. Foa, P. P., Magid, E. B., Glassman, M. D., and Weinstein, H. R.: Anterior
pituitary growth hormone (STH) and the pancreatic secretion of glucagon
(HGF). Proc. Soc. exp. Biol. (N. Y.), 1953, 83, 758.
41. Foa, P. P., Santamaria, L., Berger, S., Smith, J. A., and Weinstein, H. R.:
Effects of the hyperglycemic-glycogenolytic factor (HGF), epinephrine and
insulin in normal and depancreatized dogs. Proc. Soc. exp. Biol. (N. Y.),
1952, 80, 635.
42. Foa, P. P., Santamaria, L., Weinstein, H. R., Berger, S., and Smith, J. A.:
Secretion of the hyperglycemic-glycogenolytic factor in normal dogs. Amer.
J. Physiol., 1952, 171, 32.
43. Fora, P. P. and Weinstein, H. R.: Metabolic effects of an insulin-free pancreatic
extract. Amer. J. Physiol., 1950, 163, 711.
44. Foa, P. P. and Weinstein, H. R.: An insulin-free pancreatic extract capable of
reducing the concentration of ketone bodies in the blood. Fed. Proc., 1951,
10, 43.
45. Foa, P. P., Weinstein, H. R., and Smith, T. A.: Secretion of insulin and of a
hyperglycemic substance studied by means of a pancreatic-femoral cross cir-
culation experiment. Amer. J. Physiol., 1949, 157, 197.
46. Fodden, J. H.: The enterochromaffin and pancreatic alpha cells: a comparison.
Amer. J. clin. Path., 1953, 23, 994.
47. Fodden, J. H.: Experiments with chemicals noxious to the pancreatic alpha cell.
Amer. J. clin. Path., 1953, 23, 1002.
48. Fodden, J. H. and Read, W. O.: The activity of extracted pancreatic hyper-
glycemic-glycogenolytic factor after cobaltous chloride and synthalin A.
Endocrinology, 1954, 54, 303.
49. Geiling, E. M. K. and DeLawder, A. M.: Studies on crystalline insulin. XI. Does
insulin cause an initial hyperglycemia? J. Pharmacol., 1930, 39, 369.
50. Geschwind, I. I. and Staub, A.: Lack of growth-promoting potency and of
toxicity of glucagon (hyperglycemic-glycogenolytic factor) in hypophysec-
tomized rats. Proc. Soc. exp. Biol. (N. Y.), 1953, 84, 244.
51. Goldner, M. G., Volk, B. W., and Lazarus, S. S.: Effect of cobaltous chloride
on the blood sugar and alpha cells in the pancreatic islets of the rabbit.
Metabolism, 1952, 1, 544.
52. Goldner, M. G., Volk, B. W., and Lazarus, S. S.: Effect of a-cell destruction on
hyperglycemic glycogenolytic factor (HGF) of canine pancreas. J. clin.
Endocr. Metab., 1954, 14, 184.
53. Gomori, G.: Observations with differential stains on human islets of Langerhans.
Amer. J. Path., 1941, 17, 395.
54. Gourevitch, A., Thomas, G., and Whitfield, A. G. W.: Metabolic effects of total
pancreatectomy in man. Lancet, 1952, 262, 180.
134Glucagon (hyperglycemic-glycogenolytic factor) I CARDILLO, BONDY
55. Ham, A. W. and Haist, R. E.: Histological study of trophic effects of diabeto-
genic anterior pituitary extracts and their relation to the pathogenesis of
diabetes. Amer. J. Path., 1941, 17, 787.
56. Hastings, A. B., Teng, C. T., and Renold, A. E.: Effects of ions and hormones
on carbohydrate metabolism. Recent Progr. Hormone Res., 1955, 11, 381.
57. Haugaard, E. S. and Haugaard, N.: The effect of hyperglycemic-glycogenolytic
factor on fat metabolism of liver. J. biol. Chem., 1954, 206, 641.
58. Haugaard, E. S. and Stadie, W. C.: The effect of hyperglycemic-glycogenolytic
factor and epinephrine on fatty acid synthesis. J. biol. Chem., 1953, 200, 753.
59. Helmer, 0. M. and Root, M.: The effect of ACTH and cortisone on the hyper-
glycemic response to glucagon. Endocrinology, 1954, 54, 338.
60. Himwich, H. E.: Brain metabolism and cerebral disorders. Baltimore, The
Williams and Wilkins Company, 1951.
61. Ingle, D. J., Beary, D. F., and Purmalis, A.: Effect of continuous injection of
glucagon upon glycosuria of partially depancreatized rats. Proc. Soc. exp.
Biol. (N. Y.), 1954, 85, 432.
62. Ingle, D. J., Nezamis, J. E., and Humphrey, L. M.: Absence of hyperglycemic
effect of glucagon in the eviscerate rat. Proc. Soc. exp. Biol. (N. Y.), 1953,
84, 232.
63. Kalant, N.: Metabolic effects of the pancreatic hyperglycemic factor. Proc. Soc.
exp. Biol. (N. Y.), 1954, 86, 617.
64. Kimball, C. P. and Murlin, J. R.: Aqueous extracts of pancreas. III. Some
precipitation reactions of insulin. J. biol. Chem., 1923, 58, 337.
65. Kirtley, W. R., Waife, S. O., Helmer, 0. M., and Peck, F. B.: Effect of purified
glucagon (hyperglycemic-glycogenolytic factor, HGF) on carbohydrate and
corticoid metabolism in normal and diabetic subjects. Diabetes, 1953, 2, 345.
66. Kirtley, W. R., Waife, S. O., and Peck, F. B.: Effect of glucagon in stable and
unstable diabetic patients. Proc. Soc. exp. Biol. (N. Y.), 1953, 83, 387.
67. Lazarus, S. S., Goldner, M. G., and Volk, B. W.: Selective destruction of pan-
creatic alpha cells by cobaltous chloride in the dog. Metabolism, 1953, 2, 513.
68. Lazarus, S. S., and Volk, B. W.: Studies on hypoglycemia responsiveness.
Metabolism, 1953, 2, 500.
69. Lazarus, S. S., Volk, B. W., and CoTui.: R6le of pancreas in hypoglycemia
responsiveness and associated rise of circulating eosinophils. Proc. Soc. exp.
Biol. (N. Y.), 1952, 81, 288.
70. Levine, R. and Goldstein, M. S.: The mechanism of insulin action. Recent Progr.
Hormone Res., 1955, 11, 343.
71. Lundsgaard, E., Nielsen, N. A., and 0rskov, S. L.: Skand. Arch. Physiol., 1939,
81, 11. Quoted by De Duve. Lancet, 1953, 265, 99.
72. Mirsky, I. A.: Personal communication.
73. Mirsky, I. A., Futterman, P., Wackman, J., and Perisutti, G.: The influence of
pancreatectomy on the metabolic state of the alloxan-diabetic dog. Endo-
crinology, 1951, 49, 73.
74. Murlin, J. R., Clough, H. D., Gibbs, C. B. F., and Stokes, A. M.: Aqueous
extracts of pancreas. I. Influence on the carbohydrate metabolism of depancre-
atized animals. J. biol. Chem., 1923, 56, 253.
75. Myers, J. D., Kibler, R. F., and Taylor, W. J.: Effects of pancreatic hyper-
glycemic factor on hepatic carbohydrate metabolism of man. Fed. Proc., 1952,
11, 111.
76. Olsen, N. S. and Klein, J. R.: Hyperglycemia induced by certain insulin prepara-
tions. Proc. Soc. exp. Biol. (N. Y.), 1947, 66, 86.
77. Osman-Saka, M.: Hyperglycemic-glycogenolytic factor in diabetic man and
alloxan-diabetic animals. Amer. J. Physiol., 1952, 171, 401.
135YALE JOURNAL OF BIOLOGY AND MEDICINE Volume 28, November 1955
78. Pincus, I. J.: A hyperglycemic factor extracted from the pancreas. J. clin.
Endocr., 1950, 10, 556.
79. Pincus, I. J.: Effect of HGF on blood sugar of patients with diabetes. Proc.
Soc. exp. Biol. (N. Y.), 1950, 74, 377.
80. Pincus, I. J., Komarov, S. A., Snape, W. J., and Shay, H.: Hyperglycemic
activity of pancreatic extracts. Amer. J. Physiol., 1948, 155, 460.
81. Pincus, I. J. and Rutman, J. Z.: Glucagon, the hyperglycemic agent in pancre-
atic extracts. A possible factor in certain types of diabetes. Arch. int. Med.,
1953, 92, 666.
82. Raja Ramo Rao, M. R. and De, N. N.: Abdominal lymphatic tissue as a source
of hyperglycaemic glycogenolytic factor. Nature (Lond.), 1954, 174, 229.
83. Renold, A. E., Teng, C. T., Nesbett, F. B., and Hastings, A. B.: Studies on
carbohydrate metabolism in rat liver slices. II. The effect of fasting and of
hormonal deficiencies. J. biol. Chem., 1953, 204, 533.
84. Renold, A. E. and Hastings, A. B.: Modification du metabolisme des hydrates de
carbon dans le foie d'animaux diabetiques et dans le foie d'animaux traites
a la cortisone. Acta Endocr., 1953, 14, 47.
85. Ricketts, H. T., Brunschwig, A., and Knowlton, K.: Effects of total pancreatec-
tomy in a patient with diabetes. Amer. J. Med., 1946, 1, 229.
86. Rodriguez-Candela, J. L.: The hyperglycemic-glycogenolytic factor produced by
the pancreas. J. clin. Endocr. Metab., 1952, 12, 245.
87. Rodriguez-Candela, J. L.: Inhibitory effect of pancreas extract and HGF on
the insulin glucose uptake of the isolated diaphragm. Conference on Hormone
Factors in Carbohydrate Metabolism of the Ciba Foundation Colloquia on
Endocrinology, 1953, 6, 233.
88. Rutman, J., Pincus, I. J., Brown, L., and Scott, M.: Effect of HGF on acidosis
and lipids in intact and depancreatized dogs. Fed. Proc., 1953, 12, 121.
89. Sarzana, G. and Cascio, G.: Sul determinismo dei processi glicogenolitici con-
secutivi al trattamento con insulina. Azione dell'insulina sulle riserve di glico-
geno in condizioni di ipo- e di iper-glicemia. Arch. de Fisiologia, 1951, 51,
115.
90. Scott, D. A.: Crystalline insulin. Biochem. J., 1934, 28, 1592.
91. Shipley, R. A. and Humel, E. S., Jr.: Carbohydrate and acetone body metabolism
of liver slices and the effect of insulin. Amer. J. Physiol., 1945, 144, 51.
92. Sonenberg, M.: Studies with radioactively labelled anterior pituitary prepara-
tions. Ciba Foundation Colloquia on Endocrinology, 1952, 4, 229.
93. Staub, A., Sinn, L., and Behrens, 0. K.: Purification and crystallization of
hyperglycemic-glycogenolytic factor (HGF). Science, 1953, 117, 628.
94. Stewart, R. D. and Roitman, E.: Effect of pancreatic extracts on ketone body
production of rat liver. Endocrinology, 1953, 53, 192.
95. Sutherland, E. W.: The effect of the hyperglycemic factor of the pancreas and of
epinephrine on glycogenolysis. Recent Progr. Hormone Res., 1950, 5, 441.
96. Sutherland, E. W. and Cori, C. F.: Influence of insulin preparations on glyco-
genolysis in liver slices. J. biol. Chem., 1948, 172, 737.
97. Sutherland, E. W. and Cori, C. F.: Effect of hyperglycemic-glycogenolytic
factor and epinephrine on liver phosphorylase. J. Biol. Chem., 1951, 188, 531.
98. Sutherland, E. W., Cori, C. F., Haynes, R., and Olsen, N. S.: Purification of the
hyperglycemic-glycogenolytic factor from insulin and from gastric mucosa.
J. biol. Chem., 1949,180, 825.
99. Sutherland, E. W. and De Duve, C.: Origin and distribution of the hypergly-
cemic-glycogenolytic factor of the pancreas. J. biol. Chem., 1948, 175, 663.
100. Taubenhaus, M., Levine, R., and Soskin, S.: Effect of insulin on rate of appear-
ance of free sugar in liver brei. Proc. Soc. exp. Biol. (N. Y.), 1939, 42, 693.
136Glucagon (hyperglycemic-glycogenolytic factor) CARDILLO, BONDY
101. Terbruggen, A.: Untersuchungen uber Inselapparat und Inseladenome des Pan-
kreas, insbesondere uber die Zelltypen bei Diabetes mellitus und Spontan-
hypoglykamie. Virchows Archiv. path. Anat., 1948, 315, 407.
102. Thorogood, E. and Zimmermann, B.: The effects of pancreatectomy on glyco-
suria and ketosis in dogs made diabetic by alloxan. Endocrinology, 1945, 37,
191.
103. Tyberghein, J.: Action du glucagon sur le metabolisme des proteines. Arch. int.
Physiol., 1953, 61, 104.
104. Van Campenhout, E. and Cornelis, G.: Destruction experimentale des cellules
alpha des ilots endocrines du pancreas chez le cobaye. C. R. Soc. Biol.
(Paris), 1951, 145, 933.
105. Van Itallie, T. B., Morgan, M. C., and Dotti, L. B.: Effect of glucagon on
peripheral utilization of glucose in man. J. Clin. Endocr. Metab., 1955, 15, 28.
106. Volk, B. W., Goldner, M. G., and Lazarus, S. S.: The selective destruction of
the alpha cells by cobaltous chloride and its physiological implications. Amer.
J. Path., 1953, 29, 580.
107. Volk, B. W., Lazarus, S. S., and Goldner, M. G.: Alpha cell damage and blood
sugar changes in rabbits after administration of cobalt. Proc. Soc. exp. Biol.
(N. Y.), 1953, 82, 406.
108. Vuylsteke, C. A., Cornelis, G., and De Duve, C.: Influence du traitement au
cobalt sur le contenu en facteur HG du pancreas de cobaye. Arch. int.
Physiol., 1952, 60, 128.
109. Vuylsteke, C. A., De Duve, C., and Nys, A.: etude sur le facteur HG du pan-
creas (communication preliminaire). Arch int. Physiol., 1950, 57, 445.
110. Weisberg, H. F., Caren, R., Huddlestun, B., and Levine, R.: Effects of the
hyperglycemic-glycogenolytic factor (HGF) found in insulin preparations.
Amer. J. Physiol., 1949, 159, 98.
111. Werch, S. C. and Altschuler, S. S.: A study of the blood sugar raising sub-
stance in the urine of diabetic and non-diabetic patients. Amer. J. Physiol.,
1937, 118, 659.
112. Whipple, A. O.: Radical surgery for certain cases of pancreatic fibrosis associ-
ated with calcareous deposits. Ann. Surg., 1946, 124, 991.
113. Young, F. G.: The anterior pituitary gland and diabetes mellitus. New Engl.
J. Med., 1939, 221, 635.
114. Young, F. G.: The growth hormone and diabetes. Recent Progr. Hormone Res.,
1953, 8, 471.
115. Zimmermann, B. and Donovan, T. J.: Hyperglycemic effect of insulin. Amer. J.
Physiol., 1948, 153, 197.
137